Filing Details
- Accession Number:
- 0001415889-24-021731
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-20 18:46:23
- Reporting Period:
- 2024-08-16
- Accepted Time:
- 2024-08-20 18:46:23
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1899977 | C. Mark Schneyer | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | Evp, Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-08-16 | 5,275 | $0.00 | 39,839 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2024-08-16 | 13,629 | $0.00 | 53,468 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-08-19 | 9,733 | $15.28 | 43,735 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Footnotes
- Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
- Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
- The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Billionaire Hedge Funds
